ChemoMetec Boosts Financial Outlook with Anticipated Growth

Author: Olivia Taylor Updated: 10-28-2025 06:15 AM

ChemoMetec Boosts Financial Outlook Amid Growing Interest

ChemoMetec is excited to announce an upgrade in its financial guidance as the company sees a growing demand for its pioneering technologies, particularly the highly regarded XcytoMatic platform. This surge in interest bodes well for the company's revenue and profit, reflecting a positive trajectory as it approaches the latter half of the fiscal year.

Increased Revenue Expectations

The financial projections for the fiscal year 2025/26 have seen a promising shift, with revenue expectations revised to a range of DKK 565-580 million. This is a noticeable increase from the previously announced forecast of DKK 545-565 million. Such optimism is grounded in the trends observed and the expanding market for ChemoMetec's innovative technologies.

EBITDA Forecast Adjustment

Alongside revenue growth, ChemoMetec is also updating its EBITDA expectations. The anticipated range is now set between DKK 320-335 million, improving upon the earlier forecast of DKK 295-315 million. This upward revision indicates the firm’s solid financial health and operational efficiency in managing costs and maximizing profit potential.

Upcoming Trading Statement

The company is scheduled to release its Q1 trading statement for the fiscal year 2025/26. Investors and stakeholders can look forward to this announcement on 6 November 2025. This statement will provide further insights into the company’s performance and outlook.

Leadership Commitment

Martin Helbo Behrens, the CEO of ChemoMetec, emphasizes their commitment to delivering exceptional technology and value to their customers across various sectors including pharmaceuticals, biotechnology, and agriculture. The leadership team, which includes CFO Kim Nicolajsen, is dedicated to steering the company towards sustainable growth and innovation.

About ChemoMetec A/S

ChemoMetec has carved a niche in the development, manufacturing, and marketing of sophisticated instruments for cell counting and various measurement applications. Their products cater to a diverse array of markets, particularly focusing on pharmaceutical, biotech, and agricultural industries worldwide. Some of the leading global pharmaceutical companies rely on ChemoMetec's state-of-the-art instruments, underscoring the company's significant role in healthcare technology.

Established in 1997, ChemoMetec is publicly traded on Nasdaq OMX Copenhagen, showcasing its long-standing presence and credibility in the market. For further information about the company and its groundbreaking technologies, you can visit their official site www.chemometec.com.

Frequently Asked Questions

What recent changes have been made to ChemoMetec's financial guidance?

ChemoMetec has updated its revenue expectations for the fiscal year 2025/26, increasing the forecast to a range of DKK 565-580 million.

How does the upgraded EBITDA forecast impact ChemoMetec?

The EBITDA expectations have also been raised to DKK 320-335 million, reflecting the company's operational efficiency and positive market trends.

What technology is driving growth for ChemoMetec?

The XcytoMatic platform is currently driving significant interest and expected revenue growth for ChemoMetec.

When will ChemoMetec release its quarterly trading statement?

The trading statement for Q1 2025/26 is scheduled to be released on 6 November 2025.

What industries benefit from ChemoMetec's instruments?

ChemoMetec’s instruments are primarily utilized in the pharmaceutical, biotech, and agricultural industries.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.